Greenwoods Investment
VC Fund
Shanghai, China
Greenwoods Investment is a private equity and venture capital firm focused on early-stage investments.
- Total investments:
- 21
- Last investment:
- Lead investor:
- 14%
Last updated:
For AI agents: llms.txt
Industries Greenwoods Investment invests in
MedicalElectronicsBiotechnologyManufacturingEdTech
Stages Greenwoods Investment invests in
Series CSeries ASeries BPost-IPO EquityVenture - Series Unknown
Countries Greenwoods Investment invests in
ChinaUnited States
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Lin Ran
|
|||
Investment Focus
Industry
- Medical 3 (14%)
- Electronics 3 (14%)
- Biotechnology 3 (14%)
- Manufacturing 3 (14%)
- EdTech 2 (10%)
Stage
- Series C 7 (33%)
- Series A 5 (24%)
- Series B 3 (14%)
- Post-IPO Equity 2 (10%)
- Venture - Series Unknown 2 (10%)
Country
- China 19 (90%)
- United States 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Lin Ran
Director
|
Director | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Xihua has a multi-modal Sparrow architecture platform similar to CortexM. The research and planning projects based on the Sparrow platform include 3D face recognition vision chips, binocular vision chips, intelligent decoding Scaler chips, MCU+ perception/driver series chips, etc. | $27.4M / Series B / Nov 13, 2023 | ||
| Sangon Biotech Co. (生工生物) is engaged in the research and development of chemical synthesis of DNA.It is a high-tech Sino-foreign joint venture established in 2003. After ten years of development, Sangon has become a professional biotechnology company that integrates research and development. Chemical synthesis DNA earned reputation for Sangonin the global market.In 2006, Sangon invested 50 million to build a manufacturing and industrial base in Songjiang Industrial Park, which has been put into use. Sangon produces various products such as DNA synthesis, DNA sequencing, Gene Synthesis, peptide synthesis, chemical agents, enzymes, molecular biology kit, cultivation medium, lab consumptive material, and miniature instruments. | $290.4M / Venture - Series Unknown / Apr 19, 2023 | ||
| Core Medical Technology is a technology enterprise mainly engaged in the research, production, development, and sales of implantable left ventricular assist devices, extracorporeal ventricular assist devices, percutaneous interventional ventricular assist devices, and equipment. The company was founded in 2016 and is based in Shenzhen, China. | $29.1M / Series C / Apr 17, 2023 | ||
| RoboSense (Suteng Innovation Technology Co., Ltd.) is the world leading environment perception solutions provider of autonomous driving LiDAR. The company is striving to deliver the world with cutting-edge robotic perception solutions which can perfectly integrate premium LiDAR hardware, 3D data processing algorithms, and deep learning technology.Through constant technology innovation, the company has made possible for robots to “see” the world with excellent environment perception capability.Registered in 2014, RoboSense is founded by a group of PhDs from Harbin Institute of Technology who have been working on LiDAR technology for more than 7 years. Over the past 4 years of commercialization, RoboSense, centered around LiDAR environment Perception technology has set up a complete operation system integrating R&D, Production, and Marketing.Besides an R&D center with Operation team headquartered in Nanshan District, Shenzhen, China, the company has an R&D center in Beijing and Silicon Valley. Until April 2017, the employee base of the company has exceeded 200 people(production employee excluded) with more than 60% are Postgraduates and PhDs. For a long time, the company has maintained cooperation with world-class educational and research institutes including MIT, HKUST, Tsinghua, and HIT on talent sourcing and academic exchanges. | Venture - Series Unknown / Jun 14, 2022 | ||
| HOOSUN provides smart factory solutions and high-end intelligent equipment R & D and manufacturing service for global users. | $15.7M / Post-IPO Equity / Apr 02, 2022 | ||
| Stemirna Therapeutics is a RNA technology based drug development company designed to maximize the potential of RNA science. The company currently has more than a dozen of independently-developed mRNA drug projects, focusing on the fields of mRNA-based personalized cancer vaccines, mRNA vaccines for infectious disease, protein defects diseases, andgenetic diseases, providing cure and solutions for cancer and infectious diseases, better serving patients. | $170.1M / Jun 03, 2021 | ||
| Stemirna Therapeutics is a RNA technology based drug development company designed to maximize the potential of RNA science. The company currently has more than a dozen of independently-developed mRNA drug projects, focusing on the fields of mRNA-based personalized cancer vaccines, mRNA vaccines for infectious disease, protein defects diseases, andgenetic diseases, providing cure and solutions for cancer and infectious diseases, better serving patients. | $187.4M / Series C / Jun 03, 2021 | ||
| Yonghui Fresh Food is the central food management and supply chain integration platform. Fresh Food can fully meet the different purchasing needs of all levels and types of customers. | $152.7M / Series A / Dec 11, 2020 | ||
| Founded in 2012, Yuanfudao is the largest online live courseplatform servicing primary and secondary school students in China. With a paying userbase of over 1 million, Yuanfudao offers a comprehensive curriculum spanning fromprimary school English, Mathematical Olympiad to all-subject courses in secondaryschool. Its unique online feature and largepool of quality teachers enable students toaccess live online tutoring at home taught by national renowned teachers, benefitinghundreds of thousands of students across the country. | $1B / Series G / Oct 20, 2020 | ||
| Zifu Medical is a national high-tech enterprise focusing on the research and development, production, sales and service of high-end medical products for the digestive tract. The company has built a professional R&D team and an international R&D management platform, has undertaken a number of national and Shenzhen technological innovationprojects, and has obtained more than 100 national patents. Insisting on independent innovation and adhering to the spirit of craftsmanship, the "Dasheng" magnetically controlled capsule endoscope system series products independently developed for ten years have obtained the National Medical Products Administration NMPA Class III medical device registration and EU CE certification (EC certificate) , Widely praised by medical institutions. | $14.7M / Series C / Sep 15, 2020 | ||
| See all 21 investments → | |||
Co-Investors
Advantech Capital
2 deals together
CICC
2 deals together
CPE
2 deals together
CITIC Securities
2 deals together
DST Global
2 deals together
E Fund Management Co.,LTD.
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
SaaS Investors
112,472 investors
Health Care Investors
47,147 investors
Hardware Investors
44,475 investors
Climate Investors
43,790 investors
Consumer Investors
36,317 investors
Manufacturing Investors
26,762 investors
Biotech Investors
23,541 investors
Biotechnology Investors
20,889 investors
EdTech Investors
20,671 investors
FAQ
What does Greenwoods Investment invest in?
Greenwoods Investment invests primarily in Medical, Electronics and Biotechnology startups, most often at Series C and Series A stage. Most of the 21 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Greenwoods Investment?
Public channels for Greenwoods Investment include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Greenwoods Investment?
The team at Greenwoods Investment includes Lin Ran (Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
